EFEva Falkensammer

Eva Falkensammer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eva Falkensammer has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    DEEP-URO RA/LP: DE-Escalation of antibiotic Prophylaxis in UROlogical procedures in Robot-Assisted or Laparoscopic Prostatectomy

    by Eva Falkensammer, Elizabeth Day, Adamos Hadjivasiliou, Béla Köves, Florian Wagenlehner, Truls Erik Bjerklund Johansen, Zafer Tandogdu

  • Open Access

    Development of DEEP-URO, a Generic Research Tool for Enhancing Antimicrobial Stewardship in a Surgical Specialty

    by Eva Falkensammer, Béla Köves, Florian Wagenlehner, José Medina-Polo, Ana-María Tapia-Herrero, Elizabeth Day, Fabian Stangl, Laila Schneidewind, Jennifer Kranz, Truls Erik Bjerklund Johansen, et al.

    Introduction: The appropriate use of antibiotic prophylaxis (AP) in surgical procedures is an ongoing debate. There is a lack of evidence, and urological guidelines provide limited, procedure-specific recommendations. Our aim was to develop a generic model of an audit to define the need for AP in urological procedures, as well as in other surgical specialties. Material and Methods: Based on our experience with the Global Prevalence of Infections in Urology (GPIU) study and a literature review, we defined benchmark standards for 30-day infection rates, including sepsis, and estimated the number of patients needed to be included in a comparative study of AP versus no AP for a surgical procedure within one year. The generic study model was developed during a modified consensus process within the UTISOLVE research group. Urology departments giving and not giving AP were invited to join our development project as an extension of GPIU. Results: Radical prostatectomy was used as a model procedure. Ca. 60 urology centers performing more than 50 radical prostatectomies per year signed up. There was variation in AP practice among sites. Our own review showed that infection rates were ca. 5%, with severe infections, including sepsis, occurring in <0.5% of cases. A sample of 1825 patients would be required to achieve a 95% confidence interval half-width of ±1.0% for general infections. For sepsis, assuming an incidence of 0.5%, a sample of 2124 patients would be needed to reach a 95% confidence interval precision of ±0.30%. Enrollment of 2070 consecutive procedures would be needed to yield precisions of ±0.94% for infection and ±0.30% for sepsis. Based on the number of procedures performed and the number of interested study sites, we agreed on a prospective, multi-center, non-interventional service evaluation, expected to collect standardized data over a 3-month period. The primary outcome was defined as the 30-day incidence of infectious complications. All patients will undergo 30-day post-procedure follow-up through routine clinical care pathways. Conclusions: Our audit model is based on benchmarking of relevant outcomes. It defines how to assess AP in surgical procedures and clarifies a series of issues necessary to defend the status of a generic study model. We regard DEEP-URO to be a comprehensive, multi-center-based initiative that will help balance infection prevention with antimicrobial stewardship and improve the quality of clinical practice and personalized medicine.


  • Open Access

    A Systematic Review of the Current Evidence of the Effectiveness and Safety of Immunoprophylaxis Using Sublingual Dead Whole Bacteria to Prevent Recurrent Urinary Tract Infections (rUTIs)

    by José Medina-Polo, Ana Arrébola-Pajares, Eva Falkensammer, Zafer Tandogdu

    Background/Objectives: Recurrent urinary tract infections (rUTIs) remain a major clinical challenge, but sublingual immunoprophylaxis with inactivated whole bacteria is a promising alternative to antibiotic prophylaxis. The objective of this systematic review was to assess the efficacy and safety of sublingual bacterial vaccines. Methods: We searched MEDLINE, Cochrane CENTRAL, and Embase (January 1979–August 2025) for English-language studies evaluating bacterial vaccines for rUTI prevention. Eligible studies included adults receiving sublingual immunoprophylaxis with heat-inactivated whole bacteria. Outcomes were UTI recurrence, infection-free interval, and adverse events. Both MV140 and autovaccines were assessed. Results: Of the 262 records identified, 14 studies met the inclusion criteria (4 comparatives, including 1 randomized trial, and 10 observational studies). UTI incidence decreased from 3.2–6.8 to 0–1.5 episodes/year at 12 months. The proportion of UTI-free patients ranged from 9.8 to 90% with immunoprophylaxis versus 0 to 25% with antibiotics or placebo. At 12 months, UTI-free rates were 10–49% with autovaccines and 9.7–60% with MV140. Patients with ≥3 UTIs ranged from 14.3 to 60.2% and 20 to 56.1% with autovaccines and MV140, respectively. The RCT reported adverse events in 0–40.8% of treated patients and 50% of placebo patients, predominantly mild. Conclusions: Although the available evidence is heterogeneous and largely derived from observational studies, sublingual immunoprophylaxis with heat-inactivated whole-bacteria—either standardized (MV140) or tailored to urine culture results—appears to be an effective and safe strategy for reducing the frequency of rUTI and prolonging infection-free intervals. However, larger randomized trials are required to confirm these findings.


  • Open Access

    Systematic Review and Meta-Analysis Provide no Guidance on Management of Asymptomatic Bacteriuria within the First Year after Kidney Transplantation

    by José Medina-Polo, Eva Falkensammer, Béla Köves, Jennifer Kranz, Zafer Tandogdu, Ana María Tapia, Tommaso Cai, Florian M. E. Wagenlehner, Laila Schneidewind, Truls Erik Bjerklund Johansen

    (1) Background: Urinary tract infections (UTIs) are among the most frequent complications in kidney transplant (KT) recipients. Asymptomatic bacteriuria (ASB) may be a risk factor for UTIs and graft rejection. We aimed to evaluate available evidence regarding the benefit of screening and treatment of ASB within the first year after KT. (2) Evidence acquisition: A systematic literature search was conducted in MEDLINE, the Cochrane Library CENTRAL and Embase. Inclusion criteria were manuscripts in English addressing the management of ASB after KT. The PICO questions concerned Patients (adults receiving a KT), Intervention (screening, diagnosis and treatment of ASB), Control (screening and no antibiotic treatment) and Outcome (UTIs, sepsis, kidney failure and death). (3) Evidence synthesis: The systematic review identified 151 studies, and 16 full-text articles were evaluated. Seven were excluded because they did not evaluate the effect of treatment of ASB. There was no evidence for a higher incidence of lower UTIs, acute pyelonephritis, graft loss, or mortality in patients not treated with antibiotics for ASB. Analysis of comparative non-randomized and observational studies did not provide supplementary evidence to guide clinical recommendations. We believe this lack of evidence is due to confounding risk factors that are not being considered in the stratification of study patients.


  • Open Access

    Antimicrobial Prophylaxis in Robot-Assisted Laparoscopic Radical Prostatectomy: A Systematic Review

    by Eva Falkensammer, Ece Erenler, Truls E. Bjerklund Johansen, Lazaros Tzelves, Laila Schneidewind, Yuhong Yuan, Tommaso Cai, Bela Koves, Zafer Tandogdu

    It remains unclear whether antibiotic prophylaxis (AP) should be recommended or discouraged in robot-assisted laparoscopic radical prostatectomy (RALP) for prostate cancer (PCa). The development of microbial resistance and side effects are risks of antibiotic use. This systematic review (SR) investigates the evidence base for AP in RALP. A systematic literature search was conducted until 12 January 2023, using Embase, MEDLINE, Cochrane CENTRAL, Cochrane CDSR (via Ovid) and CINAHL for studies reporting the effect of AP on postoperative infectious complications in RALP. Of 436 screened publications, 8 studies comprising 6378 RALP procedures met the inclusion criteria. There was no evidence of a difference in the rate and severity of infective complications within 30 days after RALP surgery between different AP protocols. No studies omitted AP. For patients who received AP, the overall occurrence of postoperative infectious complications varied between 0.6% and 6.6%. The reported urinary tract infection (UTI) rates varied from 0.16% (4/2500) to 8.9% (15/169). Wound infections were reported in 0.46% (4/865) to 1.12% (1/89). Sepsis/bacteraemia and hyperpyrexia were registered in 0.1% (1/1084) and 1.6% (5/317), respectively. Infected lymphoceles (iLC) rates were 0.9% (3 of 317) in a RALP cohort that included 88.6% pelvic lymph node dissections (PLND), and 3% (26 of 865) in a RALP cohort where all patients underwent PLND. Our findings underscore that AP is being administered in RALP procedures without scientifically proven evidence. Prospective studies that apply consistent and uniform criteria for measuring infectious complications and antibiotic-related side effects are needed to ensure the comparability of results and guidance on AP in RALP.